Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 274

    1.

    Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study.

    Lautamäki R, Airaksinen KE, Seppänen M, Toikka J, Luotolahti M, Ball E, Borra R, Härkönen R, Iozzo P, Stewart M, Knuuti J, Nuutila P.

    Diabetes. 2005 Sep;54(9):2787-94.PMID: 16123370 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.

    Hällsten K, Virtanen KA, Lönnqvist F, Janatuinen T, Turiceanu M, Rönnemaa T, Viikari J, Lehtimäki T, Knuuti J, Nuutila P.

    Diabet Med. 2004 Dec;21(12):1280-7.PMID: 15569129 [PubMed - indexed for MEDLINE]Related articles

    3.

    Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.

    Iozzo P, Hallsten K, Oikonen V, Virtanen KA, Parkkola R, Kemppainen J, Solin O, Lonnqvist F, Ferrannini E, Knuuti J, Nuutila P.

    Diabetes Care. 2003 Jul;26(7):2069-74.PMID: 12832315 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.

    Hällsten K, Virtanen KA, Lönnqvist F, Sipilä H, Oksanen A, Viljanen T, Rönnemaa T, Viikari J, Knuuti J, Nuutila P.

    Diabetes. 2002 Dec;51(12):3479-85.PMID: 12453903 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin.

    Viljanen AP, Virtanen KA, Järvisalo MJ, Hällsten K, Parkkola R, Rönnemaa T, Lönnqvist F, Iozzo P, Ferrannini E, Nuutila P.

    J Clin Endocrinol Metab. 2005 Dec;90(12):6523-8. Epub 2005 Sep 27.PMID: 16189256 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.

    Virtanen KA, Hällsten K, Parkkola R, Janatuinen T, Lönnqvist F, Viljanen T, Rönnemaa T, Knuuti J, Huupponen R, Lönnroth P, Nuutila P.

    Diabetes. 2003 Feb;52(2):283-90.PMID: 12540598 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.

    Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, Yudkin JS, Ferrannini E.

    Diabetes Care. 2004 Jun;27(6):1349-57.PMID: 15161787 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study.

    Naoumova RP, Kindler H, Leccisotti L, Mongillo M, Khan MT, Neuwirth C, Seed M, Holvoet P, Betteridge J, Camici PG.

    J Am Coll Cardiol. 2007 Nov 20;50(21):2051-8. Epub 2007 Nov 5.PMID: 18021872 [PubMed - indexed for MEDLINE]Related articles

    10.

    Rosiglitazone improves exercise capacity in individuals with type 2 diabetes.

    Regensteiner JG, Bauer TA, Reusch JE.

    Diabetes Care. 2005 Dec;28(12):2877-83.PMID: 16306548 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus.

    Borra R, Lautamäki R, Parkkola R, Komu M, Sijens PE, Hällsten K, Bergman J, Iozzo P, Nuutila P.

    Metabolism. 2008 Oct;57(10):1445-51.PMID: 18803951 [PubMed - indexed for MEDLINE]Related articles

    13.

    Impact of type 2 diabetes on myocardial insulin sensitivity to glucose uptake and perfusion in patients with coronary artery disease.

    Søndergaard HM, Bøttcher M, Marie Madsen M, Schmitz O, Hansen SB, Nielsen TT, Bøtker HE.

    J Clin Endocrinol Metab. 2006 Dec;91(12):4854-61. Epub 2006 Sep 19.PMID: 16984986 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    16.

    Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.

    van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de Roos A, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW, Diamant M.

    Circulation. 2009 Apr 21;119(15):2069-77. Epub 2009 Apr 6.PMID: 19349323 [PubMed - indexed for MEDLINE]Related articles

    17.

    Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.

    Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE.

    Diabetes Care. 2003 Jun;26(6):1685-90.PMID: 12766094 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.

    McCluskey D, Touger MS, Melis R, Schleusener DS, McCluskey D.

    Clin Ther. 2004 Nov;26(11):1783-90.PMID: 15639690 [PubMed - indexed for MEDLINE]Related articles

    19.

    Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

    Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.

    Clin Ther. 2005 Aug;27(8):1181-95.PMID: 16199244 [PubMed - indexed for MEDLINE]Related articles

    20.

    Insulin improves myocardial blood flow in patients with type 2 diabetes and coronary artery disease.

    Lautamäki R, Airaksinen KE, Seppänen M, Toikka J, Härkönen R, Luotolahti M, Borra R, Sundell J, Knuuti J, Nuutila P.

    Diabetes. 2006 Feb;55(2):511-6.PMID: 16443788 [PubMed - indexed for MEDLINE]Related articlesFree article

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination